The value of NNOX’s shares increased dramatically on Thursday following Nvidia’s announcement that it acquired a stake in Nano-X Imaging Ltd (NASDAQ: NNOX). Nano-X’s stock price further increased 36.32% to $12.95 during Friday’s trading session, indicating a notable boost in investor confidence and interest in the company’s future prospects. The rise on US stock charts translated into Nano-X’s market value more than doubling within two days.
Another recent accomplishment further reinforces Nano-x’s positive outlook as its subsidiary Nanox AI Ltd. was granted FDA clearance under 510(k) for HealthFLD. In addition to streamlining the qualitative and quantitative analysis of liver attenuation from CT scans, this AI software caters specifically to patients aged 18 to 75.
HealthFLD aims to aid clinicians in the detection of fatty liver, a precursor to metabolic dysfunction-associated steatotic liver disease (MASLD), a condition prevalent among a substantial portion of the U.S. adult population. MASLD, commonly associated with obesity, cardiovascular disease, and type 2 diabetes, poses significant public health challenges.
The traditional difficulty in accurately assessing liver attenuation on contrast-enhanced scans has limited clinicians’ ability to detect non-severe cases of MASLD. HealthFLD addresses this gap by offering a reliable, non-invasive solution to support early detection and intervention, potentially improving health outcomes for affected individuals.
Nano-X emphasizes the importance of HealthFLD as the third product in Nanox AI’s suite of AI-powered population health solutions, designed to combat chronic diseases and potentially improve health outcomes. The company believes that innovative AI solutions like HealthFLD could provide substantial benefits to the biopharmaceutical industry by streamlining the identification of candidates for clinical trials of therapies for liver diseases, including MASLD.
This FDA clearance marks the third product in Nanox AI’s suite of population health solutions to receive regulatory approval, following HealthCCSng, a solution for detecting coronary artery calcium, and HealthOST, a solution for assessing vertebral compression fractures and bone mineral density. Nano-X sees these regulatory milestones as solidifying its position as a leading developer of automated AI software medical devices.
